Literature DB >> 10843672

Sustained expression of CD154 (CD40L) and proinflammatory cytokine production by alloantigen-stimulated umbilical cord blood T cells.

N C Matthews1, M Wadhwa, C Bird, F E Borras, C V Navarrete.   

Abstract

Recent data suggests that graft-versus-host disease (GVHD) is initiated by host APCs. Blockade of CD40:CD154 interactions between APCs and T cells in vivo induces T cell tolerance to host alloantigen and dramatically reduces GVHD. Because allogeneic cord blood (CB) transplantation results in a lower incidence and severity of acute GVHD compared with bone marrow transplantation, we have investigated whether CB T cells can express CD154 in response to stimulation by allogeneic monocyte-derived dendritic cells (MDDC) and have used 5- (and 6-)carboxyfluorescein diacetate succinimidyl ester (CFSE) labeling in combination with intracellular cytokine analysis to assess the proliferation and cytokine profiles of alloantigen-responsive cells. CB T cells stimulated with allogeneic MDDC showed stronger proliferation than adult blood T cells. Surface CD154 expression was detected in the actively dividing CFSElow populations of both the CD4+ and CD4- subsets and was brightest in cells that had divided the most. Assessment of supernatants from MDDC-stimulated CB and adult blood T cells showed no significant difference in the levels of either IFN-gamma or TNF-alpha, but CB T cell supernatants did show a significant lack of detectable IL-2. Intracellular cytokine analysis revealed that dividing CB T cells had been primed to produce IFN-gamma, TNF-alpha, and IL-2 on restimulation. Further phenotype analysis showed that 75% of CB T cells producing IFN-gamma were CD8+. These data suggest that MDDC-stimulated CB T cells express functional CD154 and provide enough costimulation for dendritic cells to prime naive CD8+ CB T cells and induce type 1 cytokine production.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843672     DOI: 10.4049/jimmunol.164.12.6206

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Immunofluorescence analysis of T-cell responses in health and disease.

Authors:  H T Maecker; V C Maino; L J Picker
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

2.  Development of interleukin-12-producing capacity throughout childhood.

Authors:  John W Upham; Peter T Lee; Barbara J Holt; Tricia Heaton; Susan L Prescott; Mary J Sharp; Peter D Sly; Patrick G Holt
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

3.  Differential expression of the cytokine receptors for human interleukin (IL)-12 and IL-18 on lymphocytes of both CD45RA and CD45RO phenotype from tonsils, cord and adult peripheral blood.

Authors:  M Bofill; E Almirall; A McQuaid; R Peña; R Ruiz-Hernandez; M Naranjo; L Ruiz; B Clotet; F E Borràs
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

4.  A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis.

Authors:  Nathalie Arbour; Andreas Holz; Jack C Sipe; Denise Naniche; John S Romine; Jack Zyroff; Michael B A Oldstone
Journal:  J Neuroimmunol       Date:  2003-04       Impact factor: 3.478

5.  Potential immaturity of the T-cell and antigen-presenting cell interaction in cord blood with particular emphasis on the CD40-CD40 ligand costimulatory pathway.

Authors:  P Han; T McDonald; G Hodge
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

6.  Preformed CD40 ligand exists in secretory lysosomes in effector and memory CD4+ T cells and is quickly expressed on the cell surface in an antigen-specific manner.

Authors:  Yoshinobu Koguchi; Timothy J Thauland; Mark K Slifka; David C Parker
Journal:  Blood       Date:  2007-06-26       Impact factor: 22.113

7.  The difference in immune response and IL-12p35 methylation between newborns and adults.

Authors:  Chia-Jung Chen; Jia-Woei Hou; Bor-Luen Chiang
Journal:  J Biomed Sci       Date:  2014-08-19       Impact factor: 8.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.